SOND

SOND's founder, Bose's former head of sleep, identified a critical gap: most people couldn't access real-time feedback about what was actually disrupting their sleep. Chronic poor sleepers experienced this most acutely—they'd try countless interventions without understanding their individual sleep physiology. While sleep trackers existed, they only measured after the fact; none intervened during sleep itself. The problem was measurable: Americans reported spending $585 billion annually on sleep-related issues, yet lacked actionable insights during the night when interventions mattered most. Existing alternatives—white noise machines, sleep apps, and basic wearables—operated blindly, applying generic solutions rather than responding to individual physiology. SOND's early validation came from Bose's sleep research division, which had already mapped the physiological signals affecting sleep quality. The $7M funding and stealth exit signaled investor confidence that capturing 12 simultaneous biometric signals in-ear was technically feasible and commercially viable, validating the closed-loop intervention model before full market launch.